Our extensive characterization of cancer-associated mutations in helix H3 of PPARγ LBD provides a stepping stone for the development of new biomarkers targeting tumor microenvironments and a new therapeutic approach that pharmacologically inhibits the abnormal activation of PPARγ/RXRα pathway observed in certain cancers. Here, RXRA is linked to cancer.